About Servier

Servier is a global pharmaceutical company focused on the research, development, manufacture and marketing of medicinal products in the areas of cardiovascular and chronic venous diseases, neuropsychiatric disorders, oncology and diabetes. We are number two in Europe and number eight worldwide in cardiology, with the largest product range addressing the needs of all patient profiles. To learn more about the Servier Group, please visit our corporate site.

60 Years of Embedded Experience

In 1954, Jacques Servier took over a pharmaceutical production company with nine employees in Orléans, France. Today it is France’s leading independent pharmaceutical company and the second-largest French pharmaceutical company, with 22,000 employees in 66 countries. Jacques Servier was dedicated to research and this legacy remains, with 25% of revenue and 2,900 employees dedicated to R&D.

2020

Inauguration of the Research Center in Saclay scheduled

2019

First bioproduction batches in Gidy scheduled

2017

Servier offers contract development and manufacturing services across its global network

Launch of Lonsurf in several European countries

2014

Death of the founding president

Olivier Laureau becomes President of the Servier International Research Foundation and of the Servier Group

2002

Servier is awarded the Galien Prize in recognition of its creativity in research

1996

Creation of Biogaran

1995

The first external growth operation with the acquisition of a 51% shareholding in the Hungarian company Egis Pharmaceutical

1990

The first production site outside France is built at Arklow, Ireland

1988

The journal Scrip calls Servier ‘the world’s most creative pharmaceutical company’

1972

The Gidy ‘factory village’ is built in the Loiret, and becomes Servier’s social showcase

1964

International development begins with the opening of the first subsidiary in London

1960

The Servier Research Centre opens in Suresnes

1954

Jacques Servier creates a pharmaceutical company in Orléans. A year later, the company launches its first two drugs (an antihypertensive and an antidiabetic)